New drug combo tested for Tough-to-Treat cancers
NCT ID NCT05427396
Summary
This early-stage study tested the safety of combining two experimental drugs, JS004 and toripalimab, in patients with advanced solid tumors like liver, stomach, and cervical cancer who had not responded to standard treatments. The main goal was to see if the combination was safe and tolerable, not to cure the disease. The study was terminated after enrolling 31 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER, ESOPHAGEAL SQUAMOUS CELL CARCINOMA, GASTRIC ADENOCARCINOMA, CERVICAL CANCER, MSI-H COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Conditions
Explore the condition pages connected to this study.